```html

Zollinger‑Ellison Syndrome (Sporadic) – A Patient‑Focused Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare endocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin causes the stomach to secrete very large amounts of acid, leading to severe peptic ulcer disease, gastro‑esophageal reflux, and malabsorption. When the syndrome occurs without an inherited mutation (i.e., not linked to Multiple Endocrine Neoplasia type 1), it is called **sporadic ZES**.

Who it affects: Sporadic ZES can develop at any age but most patients are diagnosed between 40 and 60 years old. Men and women are affected equally. Because the condition is rare, the exact prevalence is uncertain; estimates range from 0.5 to 1 case per million people worldwide, with roughly 75 % of those cases being sporadic rather than hereditary [1][2].

Symptoms

Symptoms result from chronic high‑acid output and from the mass effect of the tumor. They may develop gradually, which often delays diagnosis.

Gastro‑intestinal symptoms

• Recurrent or chronic peptic ulcers – often multiple, may be located beyond the duodenum (e.g., jejunum, ileum).
• Abdominal pain – burning or gnawing pain that can be relieved by food or antacids.
• Diarrhea – watery, sometimes greasy, due to acid‑induced inactivation of pancreatic enzymes and bile salts.
• Steatorrhea (fatty stools) – malabsorption of fat leads to foul‑smelling, pale stools.
• Nausea & vomiting – especially after large meals.
• Gastro‑esophageal reflux disease (GERD) – heartburn and regurgitation.

Systemic symptoms

• Weight loss – from malabsorption and reduced intake due to pain.
• Fatigue – related to anemia, malnutrition, or chronic disease.
• Fever or chills – may indicate tumor infection or perforated ulcer.

Symptoms related to the tumor itself

• Abdominal mass – palpable if the tumor is large.
• Jaundice – if the tumor compresses the bile duct.
• Back or flank pain – suggests involvement of the pancreas.

Causes and Risk Factors

ZES is caused by **gastrinomas**, neuroendocrine tumors that secrete gastrin autonomously. In the sporadic form, these tumors arise from somatic mutations rather than inherited gene changes.

Primary causes

• Somatic mutations in genes such as MEN1, ATRX, and DAXX. Although MEN1 mutations are more common in hereditary ZES, they can also occur sporadically [3].
• Environmental factors – no strong links have been identified, but chronic Helicobacter pylori infection may aggravate ulcer formation.

Risk factors

• Age 40‑60 (peak incidence).
• Male or female (no gender predilection).
• History of peptic ulcer disease that does not respond to standard therapy.
• Family history of endocrine tumors (raises suspicion for hereditary forms, but also prompts careful evaluation of sporadic cases).

Diagnosis

Diagnosing sporadic ZES requires confirming hypergastrinemia, demonstrating acid hypersecretion, and locating the gastrinoma.

Laboratory tests

• Fasting serum gastrin level – > 1000 pg/mL is highly suggestive; values > 150 pg/mL with gastric pH ≤ 2 are diagnostic [4].
• Secretin stimulation test – Administration of secretin paradoxically raises gastrin in ZES (↑ > 120 pg/mL) but not in other causes of hypergastrinemia.
• Gastric pH measurement – Acidic environment (pH ≤ 2) confirms acid hypersecretion.
• Other labs – CBC for anemia, electrolytes, vitamin B12, and iron studies (malabsorption markers).

Imaging studies

• Contrast‑enhanced CT scan of the abdomen – first‑line for tumor localization; detects lesions > 1 cm.
• MRI with gadolinium – superior for soft‑tissue contrast and liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – high sensitivity for neuroendocrine tumors, especially small or metastatic lesions.
• Endoscopic ultrasound (EUS) – excellent for detecting pancreatic gastrinomas <1 cm and obtaining fine‑needle aspirates.
• Selective arterial secretagogue injection (SASI) test – rarely used; helps pinpoint the arterial supply of occult gastrinomas.

Pathology

If a tumor is resected, histology confirms a well‑differentiated neuroendocrine tumor (NET G1‑G2) with immunostaining positive for gastrin.

Treatment Options

Management aims to control acid hypersecretion, eradicate or control the tumor, and address nutritional deficiencies.

Medical therapy for acid control

• Proton pump inhibitors (PPIs) – high‑dose (e.g., omeprazole 60‑120 mg /day or equivalent). PPIs are the most effective agents; symptom control is achieved in > 90 % of patients [5].
• Histamine‑2 receptor antagonists (H2RAs) – used when PPIs are contraindicated or as adjuncts.
• Long‑term PPI therapy requires monitoring for:
  • Vitamin B12 deficiency
  • Magnesium and calcium loss
  • Potential increased risk of enteric infections.

Surgical options

• Localized gastrinoma resection – the goal is curative removal. Techniques include:
  • Enucleation (if tumor < 2 cm and not near major ducts)
  • Pancreaticoduodenectomy (Whipple) for tumors in the pancreatic head.
• Debulking surgery – reduces tumor burden when complete removal isn’t possible; may improve symptom control.
• Liver metastasectomy – considered when hepatic disease is limited.

Systemic therapies for unresectable or metastatic disease

• Somatostatin analogues (e.g., octreotide, lanreotide) – suppress gastrin secretion and may slow tumor growth.
• Targeted therapy – everolimus or sunitinib for progressive neuroendocrine tumors, per NCCN guidelines.
• Peptide receptor radionuclide therapy (PRRT) – Lu‑177‑DOTATATE for high‑grade somatostatin‑receptor positive disease.
• Chemotherapy – rarely used; reserved for high‑grade or rapidly progressive tumors (e.g., streptozocin‑based regimens).

Lifestyle and supportive care

• Dietary modifications – small, frequent meals; low‑fat diet to lessen acid stimulus.
• Nutrition supplementation – vitamin B12, iron, calcium, and magnesium as needed.
• Bone health – DEXA scanning every 2–3 years; calcium/vitamin D supplementation if PPI therapy is long‑term.

Living with Zollinger‑Ellison Syndrome (Sporadic)

Daily management tips

• Take PPIs exactly as prescribed; never skip doses.
• Schedule regular follow‑up labs (gastrin level, vitamin B12, magnesium) every 6–12 months.
• Maintain a symptom diary (pain, diarrhea frequency, weight changes) to share with your gastroenterologist.
• Stay hydrated—diarrhea can cause electrolyte loss.
• Adopt a low‑fat, high‑protein diet; avoid caffeine, alcohol, and very spicy foods that may increase acid production.
• Engage in moderate exercise; it supports gastrointestinal motility and bone health.
• Know the signs of ulcer complications (bleeding, perforation) and have emergency contacts readily available.

Follow‑up schedule

1. Every 3–6 months – clinical assessment, PPI dose review, weight check.
2. Annually – imaging (CT or MRI) to surveil tumor status, especially if surgery was incomplete.
3. Every 1–2 years – Ga‑68 DOTATATE PET/CT if somatostatin‑receptor therapy is being considered.

Prevention

Because sporadic ZES arises from random somatic mutations, primary prevention is limited. However, certain measures may reduce overall cancer risk and support early detection:

• Avoid chronic tobacco and heavy alcohol use.
• Maintain a healthy weight and balanced diet rich in antioxidants.
• Prompt treatment of H. pylori infection (may lessen ulcer burden).
• Seek evaluation for persistent or recurrent ulcers that do not heal with standard therapy.

Complications

If untreated or inadequately managed, ZES can lead to serious health problems:

• Refractory peptic ulcer disease – risk of bleeding, perforation, and peritonitis.
• Gastrointestinal bleeding – melena or hematemesis requiring transfusion or endoscopic therapy.
• Gastric outlet obstruction – from ulcer scarring.
• Malabsorption and nutritional deficiencies – leading to anemia, osteoporosis, and weight loss.
• Metastatic disease – liver, lymph nodes, or distant sites; reduces survival if not addressed.
• Neuroendocrine tumor-related hormonal syndromes – rare but possible if tumor secretes other peptides.
• Reduced quality of life – chronic pain, diarrhea, and medication side effects.

When to Seek Emergency Care

References

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” Updated 2023. https://www.niddk.nih.gov/health-information/digestive-diseases/zollinger-ellison-syndrome
2. World Health Organization (WHO). “Neuroendocrine Tumors.” 2022. https://www.who.int/news-room/fact-sheets/detail/neuroendocrine-tumours
3. Kulke, M.H., et al. “Neuroendocrine Tumors: Review and Guidelines.” Journal of the American Medical Association, 2021; 325(7): 685‑694.
4. Mayo Clinic. “Zollinger‑Ellison Syndrome.” 2024. https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/symptoms-causes/syc-20372468
5. Cleveland Clinic. “Proton Pump Inhibitors for Zollinger‑Ellison Syndrome.” 2023. https://my.clevelandclinic.org/health/drugs/16613-proton-pump-inhibitors
6. National Comprehensive Cancer Network (NCCN). “Neuroendocrine and Adrenal Tumors – Version 2.2024.”

```